Angene®
Bionomics has developed a proprietary drug discovery platform (Angene® ) for identifying new drug targets for angiogenesis, particularly in the areas of cancer and inflammation. Angene® incorporates a variety of genomics tools and angiogenesis models for gene and drug discovery in these disease areas. Key components of this platform include:
Target Identification
Target validation in vitro
Target validation in vivo
Drug Discovery
